This review discusses several advances in melanoma therapy that have r
ecently occurred or are presently in a developmental stage. We discuss
the history and present dogma regarding assessment of the regional ly
mph nodes and adjuvant therapy for melanoma. Of special interest is ra
diolymphatic sentinel node mapping of the lymph nodes and adjuvant int
erferon alfa-2b for thick primary lesions and stage III disease. We al
so discuss several evolving novel and innovative genetic immunotherapy
approaches for patients with stage IV disease.